Battle of the bacteria busters: triple vs quadruple therapy for stomach bug

NCT ID NCT07010744

ENROLLING_BY_INVITATION Disease control Sponsor: Akil Al Islam Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests two different drug combinations to treat Helicobacter pylori, a stomach bacteria that can cause indigestion. About 66 adults with dyspepsia will receive either a triple therapy (amoxicillin, clarithromycin, esomeprazole) or a quadruple therapy (bismuth, metronidazole, tetracycline, esomeprazole) for 14 days. Researchers will check which treatment clears the infection better and track any side effects reported by patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Amoxicillin, Clarithromycin, Esomeprazole (triple therapy) vs Bismuth subcitrate, Metronidazole, Tetracycline, Esomeprazole (quadruple therapy)
What this could lead to
If successful, this could show which treatment is more effective at clearing H. pylori infection, helping doctors choose the best option for patients.
What could go wrong
This is a small, early-stage trial with only 66 participants, so results may not apply to everyone. Side effects from the drugs are possible, and the study may not find a clear winner.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DYSPEPSIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Dhaka Medical College

    Dhaka, 1000, Bangladesh

More trials for these conditions

Other studies related to the condition(s) this trial covers.